Friday, May 16, 2025 | 06:15 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid-19 vaccination: Serum Institute to gain from G7's boost to COVAX

The immediate contribution will be $2 billion. More than 180 nations are yet to administer a single dose of the Covid vaccine

New Delhi: The first batch of Covishield vaccine reaches central storage facility at Rajiv Gandhi Super Specialty hospital in New Delhi, Tuesday, Jan. 12, 2021. (PTI Photo/ Kamal Kishore)
Premium

PTI Photo/ Kamal Kishore

Ashis Ray London
Serum Institute of India (SII), which has the world’s biggest vaccine production facility, could be a major beneficiary of the G7’s decision to enhance funding to finance coronavirus vaccine supply to low- and middle-income countries.
 
India, dubbed the “pharmacy of the world”, furnishes 60 per cent of the world’s vaccines across a variety of diseases. That should compensate for any dwindling in demand in India, amid reports the immunisation effort has stumbled, because of a fall in infections and lack of confidence in a vaccine candidate approved before completing phase three trials.
 
Smisha Agarwal, a research director at

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in